TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 29141463

Group type: EXPERIMENTAL
Intervention: Paliperidone palmitate once-monthly (PP1M)
Number of subjects: 0
Study: 29141587

Group type: EXPERIMENTAL
Intervention: Video feedback using the Marte Meo method
Number of subjects: 278

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 278
Study: 29141603

Group type: EXPERIMENTAL
Intervention: UroMark assay
Number of subjects: 0
Study: 29141650

Group type: EXPERIMENTAL
Intervention: buprenorphine/naloxone
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 20
Study: 29141662

Group type: EXPERIMENTAL
Intervention: Combined autologous adipose-derived mesenchymal stem cells (AT-MSCs) and hyaluronic acid (HA) derivative, single intradiscal injection at a dose of 2 × 10.
Number of subjects: 10
Study: 29141757

Group type: EXPERIMENTAL
Intervention: Exposure to specific proteins of microorganisms
Number of subjects: 267

Group type: EXPERIMENTAL
Intervention: Natural infection and vaccination with attenuated or inactivated pathogens
Number of subjects: 267
Study: 29141853

Group type: EXPERIMENTAL
Intervention: Resistance Exercise
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 29141857

Group type: EXPERIMENTAL
Intervention: Chagasic HF
Number of subjects: 2552

Group type: COMPARATOR
Intervention: Other nonischemic cardiomyopathy
Number of subjects: 2552

Group type: COMPARATOR
Intervention: Ischemic cardiomyopathy
Number of subjects: 2552
Study: 29141948

Group type: EXPERIMENTAL
Intervention: Pralatrexate plus romidepsin
Number of subjects: 0
Study: 29142066

Group type: EXPERIMENTAL
Intervention: SGN-CD123A, an antibody-drug conjugate targeting CD123
Number of subjects: 0
Study: 29142375

Group type: EXPERIMENTAL
Intervention: Atorvastatin (40 mg for 7 days)
Number of subjects: 73

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 73
Study: 29142515

Group type: EXPERIMENTAL
Intervention: Ustekinumab 130 mg intravenous induction
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Ustekinumab ~6 mg/kg intravenous induction
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Ustekinumab 55.6% intravenous induction
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Ustekinumab 90 mg subcutaneous maintenance (q12w)
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Ustekinumab 90 mg subcutaneous maintenance (q8w)
Number of subjects: 82
Study: 29142987

Group type: EXPERIMENTAL
Intervention: Heparin-avoidance hemodialysis protocol using airless dialysis tubing
Number of subjects: 338

Group type: EXPERIMENTAL
Intervention: Heparin-avoidance hemodialysis protocol
Number of subjects: 338
Study: 29143287

Group type: EXPERIMENTAL
Intervention: Lipoic acid (LA) 1200 mg oral administration
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (implied control)
Number of subjects: 0
Study: 29143315

Group type: EXPERIMENTAL
Intervention: Hydroxycarbamide
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Autologous transplant of edited haematopoietic stem cells
Number of subjects: 0
Study: 29143565

Group type: EXPERIMENTAL
Intervention: Darunavir 800 mg once daily (QD)
Number of subjects: 1686

Group type: EXPERIMENTAL
Intervention: Darunavir 800 mg once daily (QD) with N(t)RTI backbone
Number of subjects: 1686
Study: 29143919

Group type: EXPERIMENTAL
Intervention: iGlarLixi (fixed-ratio combination of insulin glargine U100 + lixisenatide)
Number of subjects: 0

Group type: COMPARATOR
Intervention: iGlar (insulin glargine U100)
Number of subjects: 0
Study: 29144985

Group type: EXPERIMENTAL
Intervention: Rigosertib (650-1700 mg/m2) administered via continuous intravenous infusion for 3-7 days
Number of subjects: 22
Study: 29145038

Group type: EXPERIMENTAL
Intervention: Molecular targeted agents (MTAs)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 43
Study: 29145039

Group type: EXPERIMENTAL
Intervention: SAR125844 (MET kinase inhibitor) at a maximum tolerated dose (MTD) of 570 mg/m
Number of subjects: 72
Study: 29145483

Group type: EXPERIMENTAL
Intervention: M. tuberculosis-infected adolescents who developed tuberculosis disease (progressors)
Number of subjects: 150

Group type: COMPARATOR
Intervention: M. tuberculosis-infected adolescents (progressors)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: BCG re-vaccination in an independent adult cohort
Number of subjects: 150
Study: 29145602

Group type: EXPERIMENTAL
Intervention: Bevacizumab plus FUOX, FUIRI, XELIRI, or XELOX (experimental group)
Number of subjects: 195

Group type: COMPARATOR
Intervention: Bevacizumab plus XELOX (control group)
Number of subjects: 195
Study: 29145895

Group type: EXPERIMENTAL
Intervention: hs-cTnI
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: hs-cTnT
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: hs-cTnT ≥ 0.02 µg/l
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: hs-cTnI ≥ 5.5 ng/l
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: hs-cTnI and hs-cTnT
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Agatston score
Number of subjects: 76
Study: 29146021

Group type: EXPERIMENTAL
Intervention: Scales for the Assessment of Positive and Negative Symptoms (SAPS & SANS)
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Cluster analysis of symptom dimensions
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Demographic and clinical data comparison
Number of subjects: 125
Study: 29146124

Group type: EXPERIMENTAL
Intervention: Canakinumab 50 mg
Number of subjects: 10061

Group type: EXPERIMENTAL
Intervention: Canakinumab 150 mg
Number of subjects: 10061

Group type: EXPERIMENTAL
Intervention: Canakinumab 300 mg
Number of subjects: 10061

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10061
Study: 29146301

Group type: EXPERIMENTAL
Intervention: High blood eosinophil count (≥200 cells per μL)
Number of subjects: 2737

Group type: COMPARATOR
Intervention: Low blood eosinophil count (<200 cells per μL)
Number of subjects: 2737

Group type: EXPERIMENTAL
Intervention: High sputum eosinophil percentage (≥1·25%)
Number of subjects: 2737

Group type: COMPARATOR
Intervention: Low sputum eosinophil percentage (<1·25%)
Number of subjects: 2737
Study: 29146409

Group type: EXPERIMENTAL
Intervention: Lurasidone monotherapy (20 to 120 mg/day)
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Lurasidone adjunctive therapy with lithium or valproate (20 to 120 mg/day)
Number of subjects: 141
Study: 29146521

Group type: EXPERIMENTAL
Intervention: HLA-DQ-gluten tetramer-based assay
Number of subjects: 143
Study: 29146566

Group type: EXPERIMENTAL
Intervention: Peer electronic mentoring intervention (4-week, interactive intervention, moderated by peer mentors)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 29146670

Group type: EXPERIMENTAL
Intervention: Index of Microcirculatory Resistance (IMR)
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Fractional Flow Reserve (FFR)
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: CMD assessment in territories supplied by coronary vessels
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Clinical factors and epicardial coronary disease severity
Number of subjects: 93
Study: 29147135

Group type: EXPERIMENTAL
Intervention: Plecanatide 3 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Plecanatide 6 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 29147617

Group type: EXPERIMENTAL
Intervention: hu3F8 monoclonal antibody
Number of subjects: 57
Study: 29147626

Group type: EXPERIMENTAL
Intervention: Postoperative follow-up and preoperative IFN-γ T cell responses against 14 NSCLC-associated antigens
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: TAA-specific T cells characterized using TNF-α, IL-2, and IFN-γ cytokine capture assays
Number of subjects: 51
Study: 29147661

Group type: EXPERIMENTAL
Intervention: Real-time BEI feedback during rehabilitation
Number of subjects: 31

Group type: COMPARATOR
Intervention: Standard motor rehabilitation without BEI feedback
Number of subjects: 31

Group type: COMPARATOR
Intervention: Motor exercise of varying levels of difficulty
Number of subjects: 31
Study: 29147764

Group type: EXPERIMENTAL
Intervention: PET/CT
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: PET/MRI
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: mpMRI
Number of subjects: 26
Study: 29148099

Group type: EXPERIMENTAL
Intervention: Surgery (elective abdominal aortic aneurysm repair)
Number of subjects: 39
Study: 29148344

Group type: EXPERIMENTAL
Intervention: Shared incentive arm
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Physician incentive arm
Number of subjects: 0
Study: 29148821

Group type: EXPERIMENTAL
Intervention: Prior CGM group
Number of subjects: 124

Group type: COMPARATOR
Intervention: No prior CGM group
Number of subjects: 124
Study: 29149283

Group type: EXPERIMENTAL
Intervention: RotaTeq vaccine after first dose
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: RotaTeq vaccine after second dose
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: RotaTeq vaccine after third dose
Number of subjects: 158

Group type: COMPARATOR
Intervention: Wild-type rotavirus episodes
Number of subjects: 158
Study: 29149805

Group type: EXPERIMENTAL
Intervention: Esomeprazole
Number of subjects: 23470

Group type: EXPERIMENTAL
Intervention: Other PPIs
Number of subjects: 23470

Group type: EXPERIMENTAL
Intervention: H2 receptor antagonists
Number of subjects: 23470

Group type: COMPARATOR
Intervention: PPIs (including esomeprazole)
Number of subjects: 23470
Study: 29149855

Group type: EXPERIMENTAL
Intervention: VR-based upper limb rehabilitation program (10 sessions, 2 sessions/week)
Number of subjects: 10
Study: 29149866

Group type: EXPERIMENTAL
Intervention: Screening for frailty using the abbreviated Comprehensive Geriatric Assessment (aCGA)
Number of subjects: 257

Group type: EXPERIMENTAL
Intervention: Risk factors associated with frailty
Number of subjects: 257
Study: 29149867

Group type: EXPERIMENTAL
Intervention: Nasal high-flow oxygen therapy (HFOT) for 60 minutes
Number of subjects: 77

Group type: COMPARATOR
Intervention: Conventional oxygen treatment (COT) for 60 minutes
Number of subjects: 77
Study: 29149909

Group type: EXPERIMENTAL
Intervention: ATTC + ISF strategy
Number of subjects: 39

Group type: COMPARATOR
Intervention: ATTC strategy
Number of subjects: 39
Study: 29149914

Group type: EXPERIMENTAL
Intervention: Motivational interviewing-based brief intervention (MIBI) as an adjunct to usual care
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care (control condition)
Number of subjects: 0
Study: 29149958

Group type: EXPERIMENTAL
Intervention: Prolonged-release tacrolimus
Number of subjects: 1278

Group type: COMPARATOR
Intervention: Immediate-release tacrolimus
Number of subjects: 1278
Study: 29150069

Group type: EXPERIMENTAL
Intervention: Digital health intervention with electronic inhaler sensors tracking SABA use; duration: 30-day baseline followed by intervention months.
Number of subjects: 0
Study: 29150074

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 29150390

Group type: EXPERIMENTAL
Intervention: Negative PERC in patients with low implicit clinical probability
Number of subjects: 1757

Group type: EXPERIMENTAL
Intervention: Low clinical probability patients
Number of subjects: 1757
Study: 29150411

Group type: EXPERIMENTAL
Intervention: Surfactant protein D
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: CA19-9
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: CA-125
Number of subjects: 106
Study: 29150478

Group type: EXPERIMENTAL
Intervention: Early stimulation group
Number of subjects: 200

Group type: COMPARATOR
Intervention: Late stimulation group
Number of subjects: 200
Study: 29150533

Group type: EXPERIMENTAL
Intervention: ICD recipients (389 patients, 12% of ICD-eligible patients)
Number of subjects: 5276

Group type: EXPERIMENTAL
Intervention: ICD recipients
Number of subjects: 5276

Group type: COMPARATOR
Intervention: Non-ICD recipients
Number of subjects: 5276
Study: 29150536

Group type: EXPERIMENTAL
Intervention: Nicotine replacement therapy
Number of subjects: 199

Group type: EXPERIMENTAL
Intervention: Bupropion
Number of subjects: 199

Group type: EXPERIMENTAL
Intervention: Varenicline
Number of subjects: 199

Group type: EXPERIMENTAL
Intervention: Treatment regimens
Number of subjects: 199

Group type: COMPARATOR
Intervention: Cessation medications
Number of subjects: 199
Study: 29150537

Group type: EXPERIMENTAL
Intervention: Single measure model using single time point screening data
Number of subjects: 467708

Group type: EXPERIMENTAL
Intervention: Longitudinal average model using average risk factor values from periodic screening data
Number of subjects: 467708

Group type: EXPERIMENTAL
Intervention: Longitudinal summary model using average values and the variability of risk factors
Number of subjects: 467708

Group type: COMPARATOR
Intervention: Transition from single measure model to longitudinal average model
Number of subjects: 467708

Group type: COMPARATOR
Intervention: Transition from longitudinal average model to longitudinal summary model
Number of subjects: 467708
Study: 29150696

Group type: EXPERIMENTAL
Intervention: Overfeeding
Number of subjects: 26
Study: 29150712

Group type: EXPERIMENTAL
Intervention: Unacylated ghrelin in patients
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: Obestatin in hemodialysis patients
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: Unacylated ghrelin
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: Obestatin
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: Unacylated ghrelin and obestatin
Number of subjects: 153
Study: 29150783

Group type: EXPERIMENTAL
Intervention: Pediatric specialist hospitals
Number of subjects: 830830

Group type: COMPARATOR
Intervention: Other hospitals performing pediatric surgery
Number of subjects: 830830
Study: 29150842

Group type: EXPERIMENTAL
Intervention: 6% hydroxyethyl starch 130/0.4 (Volulyte)
Number of subjects: 195

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 195
Study: 29150844

Group type: EXPERIMENTAL
Intervention: Topically applied GSK2981278 ointment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 29151037

Group type: EXPERIMENTAL
Intervention: Losartan-based regimen
Number of subjects: 9193

Group type: EXPERIMENTAL
Intervention: Atenolol-based regimen
Number of subjects: 9193

Group type: EXPERIMENTAL
Intervention: ECG LVH by either Cornell product or Sokolow-Lyon voltage
Number of subjects: 9193
Study: 29151041

Group type: EXPERIMENTAL
Intervention: Post-contrast magnetic resonance angiography (PC-MRA)
Number of subjects: 34
Study: 29151054

Group type: EXPERIMENTAL
Intervention: Phenylephrine
Number of subjects: 48

Group type: COMPARATOR
Intervention: Ephedrine
Number of subjects: 48
Study: 29151439

Group type: EXPERIMENTAL
Intervention: Ticagrelor (TP)
Number of subjects: 2062

Group type: COMPARATOR
Intervention: Clopidogrel (CP)
Number of subjects: 2062
Study: 29152412

Group type: EXPERIMENTAL
Intervention: Pegylated interferon alfa-2a (PEG-IFN-α-2a)
Number of subjects: 83
Study: 29153462

Group type: EXPERIMENTAL
Intervention: BRT-HDR-19 Gy
Number of subjects: 43
Study: 29153564

Group type: EXPERIMENTAL
Intervention: Echocardiography, cardiac magnetic resonance (CMR), biomarkers (high-sensitivity troponin T and N-terminal pro-brain natriuretic peptide)
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: Myocardial response to AS in men
Number of subjects: 168
Study: 29153575

Group type: EXPERIMENTAL
Intervention: Persistent iron at 6 months post-STEMI
Number of subjects: 203
Study: 29153636

Group type: EXPERIMENTAL
Intervention: Intensified medical therapy for elevated LDH
Number of subjects: 268

Group type: EXPERIMENTAL
Intervention: Moderately elevated LDH (2.5× to 3.2× ULN)
Number of subjects: 268

Group type: COMPARATOR
Intervention: Higher levels of LDH (>3.2× ULN)
Number of subjects: 268

Group type: COMPARATOR
Intervention: Normal LDH
Number of subjects: 268

Group type: COMPARATOR
Intervention: Elevated LDH
Number of subjects: 268
Study: 29153775

Group type: EXPERIMENTAL
Intervention: Weekly Paclitaxel (90 mg/m²), Carboplatin, and Bevacizumab
Number of subjects: 46
Study: 29153823

Group type: EXPERIMENTAL
Intervention: Alirocumab (75 mg every 2 weeks, with dose increase to 150 mg every 2 weeks at week 12 if LDL-C ≥70 mg/dL at week 8)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Alirocumab
Number of subjects: 0
Study: 29153856

Group type: EXPERIMENTAL
Intervention: Viscous soluble fiber supplementation (median dose of 8.7 g/day, range 1.45-30 g/day)
Number of subjects: 1430
Study: 29153976

Group type: EXPERIMENTAL
Intervention: Pharmacoscopy-guided treatment
Number of subjects: 48

Group type: COMPARATOR
Intervention: Most recent regimen
Number of subjects: 48
Study: 29154111

Group type: EXPERIMENTAL
Intervention: PTEN expression
Number of subjects: 20
Study: 29154390

Group type: EXPERIMENTAL
Intervention: Suspected histamine intolerance
Number of subjects: 64

Group type: COMPARATOR
Intervention: Food allergy
Number of subjects: 64

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 64
Study: 29154891

Group type: EXPERIMENTAL
Intervention: Cough swabs (CS)
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Nasal swabs (NS)
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Induced sputum samples (ISS)
Number of subjects: 119

Group type: COMPARATOR
Intervention: Sputum samples (SS)
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Pain perception correlation
Number of subjects: 119
Study: 29155313

Group type: EXPERIMENTAL
Intervention: Deferasirox at an initial dose of 10 mg/kg/day, with up-titration to a maximum of 20 mg/kg/day for 52 weeks.
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Deferasirox treatment
Number of subjects: 27
Study: 29155991

Group type: EXPERIMENTAL
Intervention: PAS-LAR 60 mg monotherapy
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: PAS-LAR 60 mg with 50% reduced pegvisomant dose
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Combination of PAS-LAR and pegvisomant
Number of subjects: 61

Group type: COMPARATOR
Intervention: Control group (LA-SSAs and pegvisomant)
Number of subjects: 61
Study: 29156015

Group type: EXPERIMENTAL
Intervention: Thoracoscopic left atrial epicardial isolation ('box lesion') followed by transcatheter ablation in case of AF recurrency.
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Hybrid ablation (thoracoscopic ablation followed by transcatheter ablation).
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Isolated thoracoscopic ablation.
Number of subjects: 100
Study: 29156708

Group type: EXPERIMENTAL
Intervention: Refametinib alone
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Refametinib in combination with copanlisib
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Refametinib in combination with lapatinib
Number of subjects: 6

Group type: COMPARATOR
Intervention: HER2 inhibition (lapatinib or trastuzumab)
Number of subjects: 6
Study: 29156802

Group type: EXPERIMENTAL
Intervention: Pemetrexed plus carboplatin followed by pemetrexed maintenance therapy
Number of subjects: 0
Study: 29157224

Group type: EXPERIMENTAL
Intervention: MRI total score for findings at the AC joint, subacromial bursa and rotator cuff
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Change in MRI total score from baseline to one year follow-up
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tendinosis on MRI
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bursitis on MRI
Number of subjects: 0
Study: 29157306

Group type: EXPERIMENTAL
Intervention: 9-peptide breast cancer vaccine plus poly-ICLC
Number of subjects: 12
Study: 29157311

Group type: EXPERIMENTAL
Intervention: Ipilimumab with carboplatin/paclitaxel (CP)
Number of subjects: 30
Study: 29157582

Group type: COMPARATOR
Intervention: No treatment (untreated by CPAP)
Number of subjects: 266
Study: 29157584

Group type: EXPERIMENTAL
Intervention: IBD-AD (active state of disease)
Number of subjects: 47

Group type: COMPARATOR
Intervention: IBD-RE (remission group)
Number of subjects: 47

Group type: COMPARATOR
Intervention: HC (healthy controls)
Number of subjects: 47
Study: 29158179

Group type: EXPERIMENTAL
Intervention: Tc-325 (Hemospray)
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Definite hemostatic treatment (alone or in combination with surgery, chemotherapy, radiotherapy, or radiologic embolization)
Number of subjects: 99
Study: 29158249

Group type: EXPERIMENTAL
Intervention: Moderate-to-vigorous physical activity (MVPA)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sedentary time (ST)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Total physical activity
Number of subjects: 0
Study: 29158250

Group type: EXPERIMENTAL
Intervention: Bariatric surgery
Number of subjects: 25

Group type: COMPARATOR
Intervention: Control (14 lean individuals)
Number of subjects: 25
Study: 29158363

Group type: EXPERIMENTAL
Intervention: Nivolumab (1, 3, and 10 mg/kg)
Number of subjects: 6
Study: 29158365

Group type: EXPERIMENTAL
Intervention: Capecitabine 850 mg/m², Oxaliplatin, Celecoxib with concurrent radiation therapy
Number of subjects: 32
Study: 29158367

Group type: EXPERIMENTAL
Intervention: Necuparanib 0.5 mg/kg + gemcitabine
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Necuparanib 1 mg/kg + gemcitabine
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Necuparanib 2 mg/kg + nab-paclitaxel + gemcitabine
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Necuparanib 4 mg/kg + nab-paclitaxel + gemcitabine
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Necuparanib 5 mg/kg + nab-paclitaxel + gemcitabine
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Necuparanib 6 mg/kg + nab-paclitaxel + gemcitabine
Number of subjects: 39
Study: 29158421

Group type: EXPERIMENTAL
Intervention: Reperfusion therapy in urban hospitals (2001: 54%, 2011: not specified)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Reperfusion therapy in rural hospitals (2001: 57%, 2011: not specified)
Number of subjects: 0
Study: 29158582

Group type: EXPERIMENTAL
Intervention: SNP rs2709370
Number of subjects: 11105

Group type: EXPERIMENTAL
Intervention: SNP rs6785
Number of subjects: 11105
Study: 29158678

Group type: EXPERIMENTAL
Intervention: DFN-15 120 mg
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: DFN-15 240 mg
Number of subjects: 63

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63
Study: 29158913

Group type: EXPERIMENTAL
Intervention: Video-based family-oriented treatment for peripartum depression
Number of subjects: 12

Group type: COMPARATOR
Intervention: Historical comparison group of previously enrolled adolescent mothers
Number of subjects: 12
Study: 29158914

Group type: EXPERIMENTAL
Intervention: Unsupervised progressive strength training intervention monitored by BandCizer
Number of subjects: 15
Study: 29159083

Group type: EXPERIMENTAL
Intervention: Canagliflozin 50 mg BID
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Canagliflozin 150 mg BID
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0